Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Moody's exec: Goldman didn't tell us either

By Blake Ellis, staff reporter


(CNNMoney.com) -- During a hearing on Capitol Hill Friday, a former Moody's executive said he didn't know that hedge fund Paulson & Co. was involved in the selection of securities for a controversial Goldman Sachs portfolio.

"I did not know that and I'm fairly sure that my staff did not know either," said Eric Kolchinsky, a former managing director at Moody's who was involved in the rating of the portfolio at the center of the Goldman fraud case.

Kolchinsky testified before the Senate Homeland Security and Governmental Affairs Committee on Friday as part of its ongoing investigation of the role of credit rating agencies in the recent financial crisis. The hearing is the third in a series exploring the causes of the crisis.

The Committee's investigation coincides with fraud allegations against investment bank Goldman Sachs, which claim the firm misled investors by failing to disclose Paulson & Co.'s involvement in selecting mortgage securities for one of its portfolios, called ABACUS 2007-AC1, which Paulson & Co. was simultaneously betting against.

"It is something I would have wanted to know," Kolchinsky added. "It changes the whole dynamic of the structure when the people who are choosing it want it to blow up." To top of page

Search for Jobs

Index Last Change % Change
Dow 19,804.72 -22.05 -0.11%
Nasdaq 5,555.66 16.93 0.31%
S&P 500 2,271.89 4.00 0.18%
Treasuries 2.39 0.06 2.66%
Data as of 4:32am ET
Company Price Change % Change
Bank of America Corp... 22.63 0.58 2.63%
Ford Motor Co 12.41 0.00 0.00%
Chesapeake Energy Co... 6.98 -0.03 -0.43%
Citigroup Inc 57.39 -0.99 -1.70%
Reynolds American In... 58.00 0.32 0.55%
Data as of Jan 18
Sponsors

Sections

Irish drug maker Mallinckrodt will have to pay a $100 million fine and allow one of its competitors to produce a life-saving medication used to treat infants. The company hiked the price of the drug from $40 per vial to more than $34,000 per vial over the course of about 15 years. More

Federal Reserve Chair Janet Yellen gave her outlook on monetary policy days before Donald Trump becomes president. More

Navient, formerly part of Sallie Mae, was sued by the CFPB Wednesday for allegedly cheating borrowers out of repayment rights. More